SSRI-Induced Apathy Syndrome: A Clinical Review
- 1 May 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 10 (3) , 196-199
- https://doi.org/10.1097/00131746-200405000-00010
Abstract
The authors review the literature pertaining to selective serotonin reuptake inhibitor (SSRI)-induced apathy syndrome. A literature search of Medline and International Pharmaceutical Abstracts from 1970 to the present was performed for relevant articles. Twelve relevant case reports and one open-label treatment trial were identified. An amotivational, or apathy, syndrome has been reported in a number of patients receiving SSRI treatment over the last decade. This adverse effect has been noted to be dose-dependent and reversible, but is often unrecognized. This phenomenon has caused significant negative consequences for adults as well as social and academic difficulties in adolescents.Keywords
This publication has 7 references indexed in Scilit:
- Emotional blunting, sexual dysfunction and SSRIsInternational Journal of Neuropsychopharmacology, 2002
- Olanzapine in the Treatment of Apathy in Previously Depressed Participants Maintained With Selective Serotonin Reuptake InhibitorsThe Journal of Clinical Psychiatry, 2002
- Amotivational Syndrome Associated with Selective Serotonin Reuptake Inhibitors in Children and AdolescentsJournal of Child and Adolescent Psychopharmacology, 2001
- Apathy: a neuropsychiatric syndromeThe Journal of Neuropsychiatry and Clinical Neurosciences, 1991
- Apathy and Indifference in Patients on FluvoxamineJournal of Clinical Psychopharmacology, 1990
- Differential diagnosis and classification of apathyAmerican Journal of Psychiatry, 1990
- INTRODUCTIONAnnals of the New York Academy of Sciences, 1976